SEROPREVALENCE AND GENOTYPING OF HEPATITIS C VIRUS AMONG HOSPITAL BASED GENERAL POPULATION IN VIJAYPUR, INDIA
Objective: Hepatitis C virus (HCV) has emerged as a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. According to World Health Organization (WHO) there are 180 million people affected with HCV worldwide and about 12.5 million carriers in India. Genotypes of HCV can vary in pathogenecity and can impact on treatment outcome. Hence this study was undertaken to know the seroprevalence and different genotypes of HCV among hospital based general population in Vijaypur, Karnataka.
Methods: Study subjects were those attending various Out-Patient Department (OPD) and In-Patient Department (IPD) of Shri B. M. Patil Medical College, Hospital and Research Centre, Vijaypur, Karnataka. 5 ml of blood sample was aseptically collected in plain vial from the study subjects. Serum was separated and aliquoted in different vials. All the 1,200 serum samples were tested for HCV antibodies by third generation Enzyme Linked Immunosorbent Assay (ELISA). The serum samples positive by ELISA were tested for HCV RNA by Reverse Transcription Polymerase Chain Reaction (RT-PCR). Serum samples positive for HCV RNA were subjected to geno typing by RFLP (Restriction Fragment Length Polymorphism) and direct sequencing.
Results: Of the 1,200 samples tested, 32 (2.6%) were positive for anti-HCV antibody and 25 (2.1%) were positive for HCV RNA. HCV genotype 1 (68%) was found to be the most predominant type followed by genotype 3 (32%). The subtypes of genotype 1 were 1a and 1b, whereas subtypes of genotype 3 were 3a and 3b.
Conclusion: The seroprevalence of HCV in this study was 2.6% and HCV genotype 1 and genotype 3 were found to be the predominant genotypes respectively. For physicians, knowing the genotype of hepatitis C virus is helpful in deciding type and duration of therapy. In addition, knowledge of circulating genotypes could impact on future vaccine formulations.
2. Hepatitis C. Initiative for vaccine research. World Health Organization WHO; 2009. Available from: URL: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html. [Last accessed on 06 Aug 2011].
3. Chattopadhyay S, Hepatitis C. A major health problem of India. Curr Sci 2002;83:9.
4. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;88:2451-5.
5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
6. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991;88:5547-51.
7. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-9.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Jr GonÃ§ales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
9. Panigrahi AK, Panda SK, Dixit RK, Rao KU, Acharya SK, Dasrathy S, et al. Magnitude of hepatitis C virus infection in India: Prevalence in healthy blood donors, acute and chronic liver disease. J Med Virol 1997;51:167-74.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
11. Mishra S, Chayani N, Sarangi G, Mallick B, Patil SB. Seroprevalence of anti HCV antibody in and around Cuttack, Orissa. Indian J Med Microbiol 2002;20:40-1.
12. Bhattacharya S, Badrinath S, Hamide A, Sujatha S. Seroprevalence of hepatitis C virus in a hospital based general population in South India. Indian J Med Microbiol 2003;21:43-5.
13. Hadziyannis SJ, Jr Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
14. Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010;81:1351-7.
15. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011;364:2429-38.
16. Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006;78:452-8.
17. Raghuraman S, Abraham P. HCV genotyping in India-Quo Vadis? Indian J Med Res 2004;119:9-11.
18. Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008;8:69.
19. Nabi SG, Zaffar G, Sheikh NI, Hassan K, Hassan U. Hepatitis C virus genotypes: A plausible association with viral loads. Indian J Pathol Microbiol 2013;56:384-7.
20. Paraboni ML, Sbeghen MD, Wolff FH, Moreira LB. Risk factors for infection with different hepatitis C virus genotypes in southern Brazil. Sci World J 2012. doi: 10.1100/2012/946954. [Article in Press]
21. Pujol FH, Loureiro CL. Replacement of hepatitis C virus genotype 1b by genotype 2 over a 10 y period in venezuela. J Clin Gastroenterol 2007;41:518-20.
22. Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes and correlates with clinical response to interferon therapy. PLoS One 2009;4:e6579.
23. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type specific differences in geographic origin and disease. Hepatology 1994;19:13-8.